Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...